Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

Frank V. Fossella, Jin Soo Lee, Dong M. Shin, Maria Calayag, Martin Huber, Roman Perez-Soler, William K. Murphy, Scott Lippman, Steven Benner, Bonnie Glisson, Marvin Chasen, Waun Ki Hong, Martin Raber

Research output: Contribution to journalArticle

259 Scopus citations

Abstract

Purpose: We conducted a phase II study to determine the response to and toxicity of docetaxel (Taxotere; Rhône-Poulenc Rorer Pharmaceuticals, Inc, Collegeville, PA) in patients with advanced non-small-cell lung cancer refractory to prior platinum-containing chemotherapy (PCC) regimens. Patients and Methods: Forty-four patients with stage IIIb or IV platinum-refractory non-small-cell lung cancer were treated with 100 mg/m2 of docetaxel intravenously over 1 hour every 3 weeks. The responses of 42 of 44 patients were assessable. Most patients had a Zubrod performance status of 1; the predominant histologic type was adenocarcinoma (61%), and 91% of patients had stage IV disease. Results: Nine of 42 assessable patients (21%) achieved a partial response to treatment. The median response duration (from response to progression) was 17 weeks, and the projected median survival duration of all patients is 42 weeks (51 weeks for adenocarcinoma and 22 weeks for nonadenocarcinoma). Grade 3/ 4 neutropenia occurred in 85% of patients and was associated with fever that required intravenous antibiotics in 16% of patients (3% of cycles). Other acute side effects included easily treated hypersensitivity reactions and dermatitis. Cumulative side effects included fluid retention and neuropathy. Conclusion: Docetaxel administered at 100 mg/m2 intravenously every 3 weeks has notable activity against platinum-refractory non-small-cell lung cancer, with a 21% major response rate. Primary side effects were neutropenia, hypersensitivity, and fluid retention.

Original languageEnglish (US)
Pages (from-to)645-651
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number3
DOIs
StatePublished - Mar 1995
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Fossella, F. V., Lee, J. S., Shin, D. M., Calayag, M., Huber, M., Perez-Soler, R., Murphy, W. K., Lippman, S., Benner, S., Glisson, B., Chasen, M., Hong, W. K., & Raber, M. (1995). Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. Journal of Clinical Oncology, 13(3), 645-651. https://doi.org/10.1200/JCO.1995.13.3.645